Enhancing preclinical drug discovery with artificial intelligence

R. S.K. Vijayan; Jan Kihlberg; Jason B. Cross; Vasanthanathan Poongavanam

doi:10.1016/j.drudis.2021.11.023

Enhancing preclinical drug discovery with artificial intelligence

R. S.K. Vijayan, Jan Kihlberg, Jason B. Cross, Vasanthanathan Poongavanam

Institute for Applied Cancer Science (IACS)

Research output: Contribution to journal › Review article › peer-review

39 Scopus citations

Abstract

Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.

Original language	English (US)
Pages (from-to)	967-984
Number of pages	18
Journal	Drug Discovery Today
Volume	27
Issue number	4
DOIs	https://doi.org/10.1016/j.drudis.2021.11.023
State	Published - Apr 2022

Keywords

Artificial intelligence
Deep learning
Drug discovery
Machine learning

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2021.11.023

Cite this

@article{9fae4cef2962416cb09b7793d185dd1e,

title = "Enhancing preclinical drug discovery with artificial intelligence",

abstract = "Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.",

keywords = "Artificial intelligence, Deep learning, Drug discovery, Machine learning",

author = "Vijayan, {R. S.K.} and Jan Kihlberg and Cross, {Jason B.} and Vasanthanathan Poongavanam",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2022",

month = apr,

doi = "10.1016/j.drudis.2021.11.023",

language = "English (US)",

volume = "27",

pages = "967--984",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Enhancing preclinical drug discovery with artificial intelligence

AU - Vijayan, R. S.K.

AU - Kihlberg, Jan

AU - Cross, Jason B.

AU - Poongavanam, Vasanthanathan

PY - 2022/4

Y1 - 2022/4

N2 - Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.

AB - Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.

KW - Artificial intelligence

KW - Deep learning

KW - Drug discovery

KW - Machine learning

UR - http://www.scopus.com/inward/record.url?scp=85121248712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121248712&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2021.11.023

DO - 10.1016/j.drudis.2021.11.023

M3 - Review article

C2 - 34838731

AN - SCOPUS:85121248712

SN - 1359-6446

VL - 27

SP - 967

EP - 984

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 4

ER -

Enhancing preclinical drug discovery with artificial intelligence

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this